Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Allogene Therapeutics (ALLO) over the last 3 years, with Q2 2025 value amounting to $2.4 million.

  • Allogene Therapeutics' Asset Writedowns and Impairment fell 5225.5% to $2.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 5473.38%. This contributed to the annual value of $15.7 million for FY2024, which is 1866.36% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Asset Writedowns and Impairment of $2.4 million as of Q2 2025, which was down 5225.5% from $10.7 million recorded in Q3 2024.
  • In the past 5 years, Allogene Therapeutics' Asset Writedowns and Impairment ranged from a high of $13.2 million in Q4 2023 and a low of $2.4 million during Q2 2025
  • For the 3-year period, Allogene Therapeutics' Asset Writedowns and Impairment averaged around $7.8 million, with its median value being $7.9 million (2024).
  • Data for Allogene Therapeutics' Asset Writedowns and Impairment shows a peak YoY increase of 5225.5% (in 2025) and a maximum YoY decrease of 5225.5% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Allogene Therapeutics' Asset Writedowns and Impairment stood at $13.2 million in 2023, then decreased by 19.0% to $10.7 million in 2024, then tumbled by 77.8% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q2 2025, $10.7 million for Q3 2024, and $5.0 million during Q2 2024.